Condition Studies
Automated daily PubMed feeds of peer-reviewed research, organized by condition.
- Long COVID →
- PACVS →
- ME/CFS →
- POTS / Dysautonomia →
- MCAS →
- Gulf War Illness →
- Lyme / PTLDS →
- Other Post-Viral (Post-infectious cough, Q-fever fatigue syndrome, Post-dengue fatigue, Chikungunya post-infectious HLH, Parvovirus B19 GBS, Mycoplasma pneumoniae neurological, post-HSV encephalitis, RIME, etc.) →
Post-Viral Illness
Curated, reference-backed treatment options for Long COVID, post-viral ME/CFS, post-dengue, post-polio, chikungunya, post-Ebola, post-infectious POTS, PANS/PANDAS, and post-Zika GBS.
PAIS Cohorts
Design-verified catalogue of post-acute infection syndrome cohorts (not patients): denominator, controls, timepoints, and banked specimens made machine-readable, with gap matrices exposing where no adequate study exists.
Interventional Studies
Actively recruiting and recently completed clinical trials for PACVS, Long COVID, ME/CFS, and related conditions.
Aggregated Evidence
Cross-condition synthesis of therapeutic agents being studied, with evidence levels and linked trial data.
Alterations, Drugs & Natural Products
98-condition database (100-disease cure-vs-chronic list) of biomarkers, ranked therapeutics, natural products, and clinical trial evidence from Open Targets, HPO, ChEMBL, DGIdb, and OSMF reviews.
Medical Freedom Maps
Static, search-indexable HTML — no Vercel/Render app required. Compare procedure access pathways across jurisdictions and healthcare laws across all 50 US states (right to try, scope of practice, telehealth, regenerative medicine, and more).
HospitalCompare
Compare CMS hospital quality ratings and shoppable procedure prices (cash-pay and insured estimates) by ZIP — knee replacement, colonoscopy, MRI, and more.
Condition-Specific Biomarkers
Peer-reviewed biomarker databases for Long COVID, PACVS, ME/CFS, Lyme disease, and Gulf War Illness. Searchable blood test alterations, cytokine panels, metabolites, and CSF markers with DOI citations.
Candidate Therapeutic Agents
Evidence-based review of investigational therapeutic agents for Long COVID, PACVS, ME/CFS, POTS, and MCAS. Filterable by condition, mechanism, and evidence tier with clinical trial data and mechanistic rationale.
PeptideOS
Disinterested evidence on therapeutic peptides: efficacy tiers, regulatory status, purity data. Class A (approved) through Class C (gray market). No dosing advice, no vendors, funded by grants only.
NTD Intelligence
The 21 WHO neglected tropical disease groups — burden, top therapeutic hits, and documented post-infectious syndromes with literature persistence rates (dengue, chikungunya, Chagas, leishmaniasis, and more).